<p>Savara Inc.（納斯達克代碼：SVRA - 免費報告）- HC Wainwright 的投資分析師在 12 月 23 日（星期二）發佈的研究報告中上調了 Savara 2027 財年的每股收益（EPS）預期。HC Wainwright 的分析師 A. Fein 現在預測該公司在該年度的每股收益為（$0.16），高於之前預測的（$0.18）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 $10.00。Savara 當前全年的共識收益預期為每股（$0.45）。HC Wainwright 還對 Savara 2028 財年的收益預期為每股 $0.13。</p>
<p>其他分析師最近也發佈了關於該股票的報告。瑞銀集團在星期二的研究報告中將 Savara 的目標價設定為 $10.00。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Savara 的 “賣出（d-）” 評級。Oppenheimer 在星期二的研究報告中將 Savara 的目標價設定為 $10.00。JMP Securities 在 10 月 23 日（星期四）的報告中將 Savara 的目標價從 $8.00 上調至 $11.00，並給予該股票 “市場表現優於大盤” 的評級。最後，富國銀行在 12 月 18 日（星期四）的報告中將 Savara 的目標價從 $7.00 上調至 $9.00，並給予該公司 “增持” 評級。一位研究分析師對該股票給予了強烈買入評級，七位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Savara 目前的平均評級為 “適度買入”，共識目標價為 $9.13。</p>
<p><strong>閲讀我們關於 Savara 的最新股票報告</strong></p>
<h2>Savara 股票表現</h2>
<p>Savara 股票在星期四開盤價為 $6.40。Savara 的 52 周低點為 $1.89，52 周高點為 $7.01。該公司的速動比率為 7.65，流動比率為 7.65，債務與股本比率為 0.32。該公司的 50 日移動平均線為 $5.12，200 日移動平均線為 $3.66。該公司的市值為 13 億美元，市盈率為 -12.07，貝塔值為 0.23。</p>
<p>Savara（納斯達克代碼：SVRA - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了其財報。該公司報告的季度每股收益為（$0.14），低於分析師的共識預期（$0.13）$0.01。</p>
<h2>機構投資者對 Savara 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對 SVRA 的持股。保誠金融公司在第二季度購買了 Savara 的新股份，價值約 $30,000。法國巴黎銀行金融市場在第二季度將其在 Savara 的持股增加了 52.3%。法國巴黎銀行金融市場目前擁有 13,473 股該公司的股票，價值 $31,000，此前在該期間內又購買了 4,626 股。May Hill Capital LLC 在第二季度購買了 Savara 的新股份，價值 $32,000。Brevan Howard Capital Management LP 在第二季度購買了 Savara 的新股份，價值 $33,000。最後，拉塞爾投資集團在第三季度將其在 Savara 的持股增加了 930.5%。拉塞爾投資集團目前擁有 10,480 股該公司的股票，價值 $37,000，此前在該期間內又購買了 9,463 股。目前，87.93% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Savara</h2>
<p>（獲取免費報告）</p>
<p>Savara Inc（納斯達克代碼：SVRA）是一家臨牀階段的生物製藥公司，專注於開發和商業化針對罕見呼吸疾病的療法。該公司專注於引進、推進並可能將新療法推向市場，以應對具有高度未滿足醫療需求的嚴重肺部疾病。</p>
<p>該公司的主要候選藥物 Molgradex（重組人粒細胞 - 巨噬細胞集落刺激因子，或 GM-CSF）正在接受監管審查，用於治療自身免疫性肺泡蛋白沉積症（PAP），這是一種以表面活性劑積累為特徵的罕見肺病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Savara 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉人工智能，這將是下一個重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Savara 嗎？</h2>
<p>在你考慮 Savara 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Savara 並不在名單上。</p>
<p>雖然 Savara 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>查看這五隻股票</p>

SVRA

<p>HC Wainwright 將 Savara Inc. 的 2027 財年每股收益（EPS）預估從（$0.18）上調至（$0.16）。該公司維持 “買入” 評級，目標價為 $10.00。其他分析師的評級則各有不同，平均目標價為 $9.13。Savara 的股票開盤價為 $6.40，52 周價格區間為 $1.89 至 $7.01。該公司專注於罕見呼吸疾病的治療，其主要候選藥物正在接受監管審查</p>

<p>Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday, December 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.18). HC Wainwright has a &#34;Buy&#34; rating and a $10.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2028 earnings at $0.13 EPS.</p>
<div class="lb-trans"><p>Savara Inc.（納斯達克代碼：SVRA - 免費報告）- HC Wainwright 的投資分析師在 12 月 23 日（星期二）發佈的研究報告中上調了 Savara 2027 財年的每股收益（EPS）預期。HC Wainwright 的分析師 A. Fein 現在預測該公司在該年度的每股收益為（$0.16），高於之前預測的（$0.18）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 $10.00。Savara 當前全年的共識收益預期為每股（$0.45）。HC Wainwright 還對 Savara 2028 財年的收益預期為每股 $0.13。</p>
</div><p>Other analysts have also recently issued reports about the stock. UBS Group set a $10.00 target price on shares of Savara in a research report on Tuesday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Savara in a research note on Wednesday, October 8th. Oppenheimer set a $10.00 price objective on Savara in a research report on Tuesday. JMP Securities lifted their target price on Savara from $8.00 to $11.00 and gave the stock a &#34;market outperform&#34; rating in a report on Thursday, October 23rd. Finally, Wells Fargo &amp; Company increased their price target on Savara from $7.00 to $9.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Savara presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.13.</p>
<div class="lb-trans"><p>其他分析師最近也發佈了關於該股票的報告。瑞銀集團在星期二的研究報告中將 Savara 的目標價設定為 $10.00。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Savara 的 “賣出（d-）” 評級。Oppenheimer 在星期二的研究報告中將 Savara 的目標價設定為 $10.00。JMP Securities 在 10 月 23 日（星期四）的報告中將 Savara 的目標價從 $8.00 上調至 $11.00，並給予該股票 “市場表現優於大盤” 的評級。最後，富國銀行在 12 月 18 日（星期四）的報告中將 Savara 的目標價從 $7.00 上調至 $9.00，並給予該公司 “增持” 評級。一位研究分析師對該股票給予了強烈買入評級，七位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，Savara 目前的平均評級為 “適度買入”，共識目標價為 $9.13。</p>
</div><p><strong>Read Our Latest Stock Report on Savara</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Savara 的最新股票報告</strong></p>
</div><h2>Savara Price Performance</h2>
<div class="lb-trans"><h2>Savara 股票表現</h2>
</div><p>Savara stock opened at $6.40 on Thursday. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm's fifty day moving average is $5.12 and its 200 day moving average is $3.66. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -12.07 and a beta of 0.23.</p>
<div class="lb-trans"><p>Savara 股票在星期四開盤價為 $6.40。Savara 的 52 周低點為 $1.89，52 周高點為 $7.01。該公司的速動比率為 7.65，流動比率為 7.65，債務與股本比率為 0.32。該公司的 50 日移動平均線為 $5.12，200 日移動平均線為 $3.66。該公司的市值為 13 億美元，市盈率為 -12.07，貝塔值為 0.23。</p>
</div><p>Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01).</p>
<div class="lb-trans"><p>Savara（納斯達克代碼：SVRA - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了其財報。該公司報告的季度每股收益為（$0.14），低於分析師的共識預期（$0.13）$0.01。</p>
</div><h2>Institutional Investors Weigh In On Savara</h2>
<div class="lb-trans"><h2>機構投資者對 Savara 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Prudential Financial Inc. bought a new stake in shares of Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares during the period. May Hill Capital LLC bought a new stake in shares of Savara during the second quarter worth $32,000. Brevan Howard Capital Management LP bought a new stake in shares of Savara during the second quarter worth $33,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after purchasing an additional 9,463 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對 SVRA 的持股。保誠金融公司在第二季度購買了 Savara 的新股份，價值約 $30,000。法國巴黎銀行金融市場在第二季度將其在 Savara 的持股增加了 52.3%。法國巴黎銀行金融市場目前擁有 13,473 股該公司的股票，價值 $31,000，此前在該期間內又購買了 4,626 股。May Hill Capital LLC 在第二季度購買了 Savara 的新股份，價值 $32,000。Brevan Howard Capital Management LP 在第二季度購買了 Savara 的新股份，價值 $33,000。最後，拉塞爾投資集團在第三季度將其在 Savara 的持股增加了 930.5%。拉塞爾投資集團目前擁有 10,480 股該公司的股票，價值 $37,000，此前在該期間內又購買了 9,463 股。目前，87.93% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Savara</h2>
<div class="lb-trans"><h2>關於 Savara</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.</p>
<div class="lb-trans"><p>Savara Inc（納斯達克代碼：SVRA）是一家臨牀階段的生物製藥公司，專注於開發和商業化針對罕見呼吸疾病的療法。該公司專注於引進、推進並可能將新療法推向市場，以應對具有高度未滿足醫療需求的嚴重肺部疾病。</p>
</div><p>The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 Molgradex（重組人粒細胞 - 巨噬細胞集落刺激因子，或 GM-CSF）正在接受監管審查，用於治療自身免疫性肺泡蛋白沉積症（PAP），這是一種以表面活性劑積累為特徵的罕見肺病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Savara</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Savara 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘掉人工智能，這將是下一個重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SVRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Savara Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Savara 嗎？</h2>
</div><p>Before you consider Savara, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Savara 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Savara 並不在名單上。</p>
</div><p>While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Savara 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

HC Wainwright 對 Savara 2027 財年收益的預測是什麼？